Earnings Alerts

Shanghai Pharmaceuticals Holding (601607) Earnings Fall Short: FY Net Income at 4.55 Billion Yuan

  • Shanghai Pharma reported a full-year net income of 4.55 billion yuan.
  • Analyst estimates for net income were higher, at 4.85 billion yuan.
  • The company’s operating revenue was 275.25 billion yuan.
  • This revenue figure also fell short of the estimated 279.72 billion yuan.
  • Among analysts, Shanghai Pharma received 10 buy ratings, 2 hold ratings, and 1 sell rating.

A look at Shanghai Pharmaceuticals Holding Smart Scores

FactorScoreMagnitude
Value5
Dividend4
Growth3
Resilience3
Momentum2
OVERALL SMART SCORE3.4

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Shanghai Pharmaceuticals Holding Co., Ltd, a company that specializes in manufacturing pharmaceuticals including chemical and Chinese traditional medicines, healthcare products, and more, has been assessed using Smartkarma Smart Scores. The scores reflect various aspects of the company’s outlook for the long term. Notably, Shanghai Pharmaceuticals Holding received a top score of 5 for its Value, indicating a strong valuation perspective. This suggests that the company may be considered undervalued relative to its financial metrics and market position.

Additionally, in terms of Dividend potential, Shanghai Pharmaceuticals Holding achieved a score of 4, highlighting its ability to provide consistent and attractive dividend yields to investors. Looking at Growth and Resilience, the company received scores of 3, indicating a moderate outlook in these areas. Finally, with a score of 2 for Momentum, Shanghai Pharmaceuticals Holding may have some challenges in terms of short-term performance and market sentiment. Overall, the company’s scores suggest a promising long-term outlook supported by strong value and dividend prospects.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars